Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis

2021年10月29日

作者 Colin McCall 以及 Nabil Asaad, PhD

点击此处了解更多
私募股权

Advising Rutland Partners on JSM Group investment

2021年2月26日

作者

点击此处了解更多
酒店与休闲

Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies

2021年2月16日

作者

点击此处了解更多
酒店与休闲

Edison Open House Global Healthcare 2021 – key takeaways from our panel

2021年2月4日
Quick read

作者

点击此处了解更多

与我会面: